Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Preferred Developer Status

17 Jan 2008 07:00

CareCapital Group plc17 January 2008 Embargoed: for release at 07.00, 17 January 2008 CareCapital Group Plc ("CareCapital") Investment and Development Programme in the UK Successful bid on two Medical Centres CareCapital, the AIM listed healthcare real estate company, announces that ithas been selected as the preferred developer for the provision of a £4.1 millionnew build medical centre in Heswall and a new medical centre in West Wirralexceeding £5 million. The 1,556 sq metre Heswall project will accommodate six GPs together with arange of support services. The current development programme anticipatesconstruction starting before the end of 2008 with the new facility becomingoperational in December 2009. The 2,241 sq metre West Wirral development will house a ten GP Practice andancillary medical facilities. The development programme is on a similar timelineto the Heswall project. Paul Stacey, Chief Executive of CareCapital commented: "It is very pleasing tohave been selected as preferred developer on these two exciting projects. We arelooking forward to working with all the stakeholders, including the Doctors andthe Primary Care Trust, to bring the developments to fruition in the shortestpossible timespan. These projects further strengthen our current businesspipeline; as the Company continues to expand its investment and developmentprogramme in both the UK and Germany." -ends- For further information please visit www.carecapital.co.uk or contact: Paul Stacey, Managing Director Lindsay Mair, Director Simon Hudson,Shareen Courtney, Marketing - Corporate Finance Paul Youens, Paul Young CareCapital Group Plc Daniel Stewart & Co. Plc Tavistock Communications Tel: 020 7034 1949 Tel: 020 7776 6550 Tel: 020 7920 3150 or 07966 477256 pstacey@carecapital.co.uk lindsay.mair@danielstewart.co.uk shudson@tavistock.co.ukscourtney@carecapital.co.uk pyouens@tavistock.co.uk pyoung@tavistock.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.